About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 783297, 5 pages
http://dx.doi.org/10.1155/2010/783297
Research Article

Postnatal BDNF Expression Profiles in Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by MK-801 Administration

1Key Laboratory of Mental Health, Institute of Mental Health, Peking University, Beijing 100191, China
2Department of Psychopharmacology, Institute of Mental Health, Peking University, Beijing 100191, China

Received 18 April 2010; Accepted 10 May 2010

Academic Editor: Xudong Huang

Copyright © 2010 Chunmei Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Weinberger, “On the plausibility of “the neurodevelopmental hypothesis” of schizophrenia,” in Proceedings of the Symposium on a New Understanding: Neurological Basis and Long-Term Outcome of Schizophrenia, at the CINP Congress, Elsevier Science, Washington, DC, USA, 1994.
  2. A. E. Rehn and S. M. Rees, “Investigating the neurodevelopmental hypothesis of schizophrenia,” Clinical and Experimental Pharmacology and Physiology, vol. 32, no. 9, pp. 687–696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. B. D. Pearce, “Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms,” Molecular Psychiatry, vol. 6, no. 6, pp. 634–646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Cannon, P. B. Jones, and R. M. Murray, “Obstetric complications and schizophrenia: historical and meta-analytic review,” American Journal of Psychiatry, vol. 159, no. 7, pp. 1080–1092, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. C. S. Weickert and D. R. Weinberger, “A candidate molecule approach to defining developmental pathology in schizophrenia,” Schizophrenia Bulletin, vol. 24, no. 2, pp. 303–316, 1998. View at Scopus
  6. P. Ernfors, C. Wetmore, L. Olson, and H. Persson, “Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family,” Neuron, vol. 5, no. 4, pp. 511–526, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Hofer, S. R. Pagliusi, A. Hohn, J. Leibrock, and Y.-A. Barde, “Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain,” EMBO Journal, vol. 9, no. 8, pp. 2459–2464, 1990. View at Scopus
  8. E. J. Huang and L. F. Reichardt, “Neurotrophins: roles in neuronal development and function,” Annual Review of Neuroscience, vol. 24, pp. 677–736, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. G. R. Lewin and Y.-A. Barde, “Physiology of the neurotrophins,” Annual Review of Neuroscience, vol. 19, pp. 289–317, 1996. View at Scopus
  10. B. Lu, “BDNF and activity-dependent synaptic modulation,” Learning and Memory, vol. 10, no. 2, pp. 86–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. K. McAllister, “Subplate neurons: a missing link among neurotrophins, activity, and ocular dominance plasticity?” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 13600–13602, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-M. Poo, “Neurotrophins as synaptic modulators,” Nature Reviews Neuroscience, vol. 2, no. 1, pp. 24–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Durany, T. Michel, R. Zöchling et al., “Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses,” Schizophrenia Research, vol. 52, no. 1-2, pp. 79–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Shoval and A. Weizman, “The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia,” European Neuropsychopharmacology, vol. 15, no. 3, pp. 319–329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. S. Weickert, T. M. Hyde, B. K. Lipska, M. M. Herman, D. R. Weinberger, and J. E. Kleinman, “Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia,” Molecular Psychiatry, vol. 8, no. 6, pp. 592–610, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Wiseman Harris, T. Sharp, J. Gartlon, D. N. C. Jones, and P. J. Harrison, “Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism,” European Journal of Neuroscience, vol. 18, no. 6, pp. 1706–1710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Adams and B. Moghaddam, “Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine,” Journal of Neuroscience, vol. 18, no. 14, pp. 5545–5554, 1998. View at Scopus
  18. R. E. Steinpreis, J. D. Sokolowski, A. Papanikolaou, and J. D. Salamone, “The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat,” Pharmacology Biochemistry and Behavior, vol. 47, no. 3, pp. 579–585, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Wolf, “The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants,” Progress in Neurobiology, vol. 54, no. 6, pp. 679–720, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. Y.-A. Su, T.-M. Si, D.-F. Zhou et al., “Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A/2C receptors,” European Journal of Pharmacology, vol. 564, no. 1–3, pp. 123–130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L. P. Spear, “The adolescent brain and age-related behavioral manifestations,” Neuroscience and Biobehavioral Reviews, vol. 24, no. 4, pp. 417–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Webster, C. S. Weickert, M. M. Herman, and J. E. Kleinman, “BDNF mRNA expression during postnatal development, maturation and aging of the human prefrontal cortex,” Developmental Brain Research, vol. 139, no. 2, pp. 139–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Danielyan and H. A. Nasrallah, “Neurological disorders in schizophrenia,” Psychiatric Clinics of North America, vol. 32, no. 4, pp. 719–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. L. M. Monteggia, B. Luikart, M. Barrot et al., “Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors,” Biological Psychiatry, vol. 61, no. 2, pp. 187–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Wang, J. McInnis, M. Ross-Sanchez, P. Shinnick-Gallagher, J. L. Wiley, and K. M. Johnson, “Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia,” Neuroscience, vol. 107, no. 4, pp. 535–550, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Takahashi, O. Shirakawa, K. Toyooka et al., “Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients,” Molecular Psychiatry, vol. 5, no. 3, pp. 293–300, 2000. View at Scopus
  28. H. Kang and E. M. Schuman, “Long-lasting neuratrophin-induced enhancement of synaptic transmission in the adult hippocampus,” Science, vol. 267, no. 5204, pp. 1658–1662, 1995. View at Scopus
  29. M. Takahashi, A. Kakita, T. Futamura et al., “Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment,” Journal of Neurochemistry, vol. 99, no. 3, pp. 770–780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Xia, C. Z. Wang, J. Liu, N. C. Anastasio, and K. M. Johnson, “Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways,” Neuropharmacology, vol. 58, no. 2, pp. 330–336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. C. Jockers-Scherübl, H. Danker-Hopfe, R. Mahlberg et al., “Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse,” Neuroscience Letters, vol. 371, no. 1, pp. 79–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Pirildar, A. S. Gönül, F. Taneli, and F. Akdeniz, “Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 4, pp. 709–713, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. T. B. Franklin and T. S. Perrot-Sinal, “Sex and ovarian steroids modulate brain-derived neurotrophic factor (BDNF) protein levels in rat hippocampus under stressful and non-stressful conditions,” Psychoneuroendocrinology, vol. 31, no. 1, pp. 38–48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Wong, M. J. Webster, H. Cassano, and C. S. Weickert, “Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex,” European Journal of Neuroscience, vol. 29, no. 7, pp. 1311–1322, 2009. View at Publisher · View at Google Scholar · View at Scopus